Fig. 6
From: ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry
ASCL1 is a member of CRC in the ADRN subtype of neuroblastoma. a Schematic image for neural differentiation and ASCL1 expression. b The mRNA expression of ASCL1 in normal neural crest, neural progenitor cells, adrenal gland, and neuroblastoma tumors (Kocak cohort31) were analyzed by the R2 database. The sample numbers are indicated. Data are presented as box plots where the middle line indicates the median, the lower, and upper hinges correspond to the first and third quartiles, the lowest datum indicates the minimum (within the 1.5 IQR of the lower quartile), and the highest datum indicate the maximum (within the 1.5 IQR of the upper quartile). The p value by one-way ANOVA followed by Tukey's multiple comparisons post hoc test are indicated in b and c. ****p value < 0.0001. c The dot pot for enhancer ranking in neuroblastoma cell lines (24 ADRN subtype neuroblastoma cell lines, 4 intermediate subtype neuroblastoma cell lines, 3 MES subtype neuroblastoma cell lines). Enhancers were ranked based on H3K27ac signal from high to low. Data are represented as means ± SEM. d The ASCL1-bound gene loci were first selected in Kelly cells. Density plots show the distribution of LMO1, MYCN, GATA3, H3K27ac, and H3K4me1 signals at the ASCL1-bound regions (±5 kb from binding sites) in Kelly cells. The color scale shows the intensity of the distribution signal. ChIP-seq gene tracks showing the binding locations of ASCL1 together with various transcription factors at the ASCL1 (e), GATA3 (f), LMO1 (g), PHOX2B (h), and HAND2 (i) gene loci in Kelly cells. Red arrows (top) indicate ASCL1-bound peak regions, which were determined by peak calling.
